The Vaccine Platform
Hawaii Biotech’s protein production platform for developing vaccines targeting infectious diseases is well suited to meet the multiple requirements of safety, efficacy, rapid response, and economics of manufacturing. Our current focus is particularly on the development of multivalent vaccines that target multiple members within a family/group of viruses.
The Company’s vaccine technology is based on the production of recombinant proteins using stable insect cell lines and the use of standardized processes for purification. The consistently high quality of the proteins produced in this system results in immune responses equivalent to or better than traditional live-attenuated or inactivated virus approaches. Furthermore, the purified recombinant proteins provide a significantly improved safety profile and opportunities for difficult select populations such as the immunocompromised. This platform technology is applicable to a wide variety of viruses including Chikungunya, Crimean-Congo hemorrhagic fever, Ebola, Eastern equine encephalitis, Japanese encephalitis, coronaviruses, dengue fever, West Nile, tick-borne flaviviruses, and others. We are currently developing formulations of vaccine candidates for several of these emerging and re-emerging viral diseases.
Hawaii Biotech’s protein production platform for developing vaccines targeting infectious diseases is well suited to meet the multiple requirements of safety, efficacy, rapid response, and economics of manufacturing. Our current focus is particularly on the development of multivalent vaccines that target multiple members within a family/group of viruses.
The Company’s vaccine technology is based on the production of recombinant proteins using stable insect cell lines and the use of standardized processes for purification. The consistently high quality of the proteins produced in this system results in immune responses equivalent to or better than traditional live-attenuated or inactivated virus approaches. Furthermore, the purified recombinant proteins provide a significantly improved safety profile and opportunities for difficult select populations such as the immunocompromised. This platform technology is applicable to a wide variety of viruses including Chikungunya, Crimean-Congo hemorrhagic fever, Ebola, Eastern equine encephalitis, Japanese encephalitis, coronaviruses, dengue fever, West Nile, tick-borne flaviviruses, and others. We are currently developing formulations of vaccine candidates for several of these emerging and re-emerging viral diseases.